Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

Hdl Handle:
http://hdl.handle.net/10147/207092
Title:
Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.
Authors:
Costello, R W; Long, D A; Gaine, S; Mc Donnell, T; Gilmartin, J J; Lane, S J
Affiliation:
Departments of Respiratory, Medicine Beaumont Hospital, Dublin 9, Ireland., rcostello@rcsi.ie
Citation:
Ir J Med Sci. 2011 Sep;180(3):637-41. Epub 2011 May 11.
Journal:
Irish journal of medical science
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207092
DOI:
10.1007/s11845-011-0716-2
PubMed ID:
21557095
Abstract:
BACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 +/- 0.41 to 0.8 +/- 0.37 and the mean number of bed days occupied was reduced from 16.6 +/- 2.94 to 5.3 +/- 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 +/- 0.27 to 1.2 +/- 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
Language:
eng
MeSH:
Adult; Aged; Anti-Asthmatic Agents/*therapeutic use; Antibodies, Anti-Idiotypic/*therapeutic use; Antibodies, Monoclonal, Humanized/*therapeutic use; Asthma/drug therapy/economics/*prevention & control; Disease Progression; Female; Hospitalization/statistics & numerical data; Humans; Length of Stay; Male; Middle Aged; Respiratory Function Tests
ISSN:
1863-4362 (Electronic); 0021-1265 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorCostello, R Wen_GB
dc.contributor.authorLong, D Aen_GB
dc.contributor.authorGaine, Sen_GB
dc.contributor.authorMc Donnell, Ten_GB
dc.contributor.authorGilmartin, J Jen_GB
dc.contributor.authorLane, S Jen_GB
dc.date.accessioned2012-02-01T09:59:02Z-
dc.date.available2012-02-01T09:59:02Z-
dc.date.issued2012-02-01T09:59:02Z-
dc.identifier.citationIr J Med Sci. 2011 Sep;180(3):637-41. Epub 2011 May 11.en_GB
dc.identifier.issn1863-4362 (Electronic)en_GB
dc.identifier.issn0021-1265 (Linking)en_GB
dc.identifier.pmid21557095en_GB
dc.identifier.doi10.1007/s11845-011-0716-2en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207092-
dc.description.abstractBACKGROUND: Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma. AIMS: The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication. METHODS: This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients. RESULTS: Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 +/- 0.41 to 0.8 +/- 0.37 and the mean number of bed days occupied was reduced from 16.6 +/- 2.94 to 5.3 +/- 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 +/- 0.27 to 1.2 +/- 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was <euro>834. CONCLUSIONS: Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAnti-Asthmatic Agents/*therapeutic useen_GB
dc.subject.meshAntibodies, Anti-Idiotypic/*therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Humanized/*therapeutic useen_GB
dc.subject.meshAsthma/drug therapy/economics/*prevention & controlen_GB
dc.subject.meshDisease Progressionen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHospitalization/statistics & numerical dataen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLength of Stayen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshRespiratory Function Testsen_GB
dc.titleTherapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.en_GB
dc.contributor.departmentDepartments of Respiratory, Medicine Beaumont Hospital, Dublin 9, Ireland., rcostello@rcsi.ieen_GB
dc.identifier.journalIrish journal of medical scienceen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.